MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/03007995.2021.1981278

Медицинская библиотека · Current medical research and opinion · 2021

Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis.

Gauthier Genevieve, Levin Rebecca, Vekeman Francis, Reyes Juan Manuel, Chiarello Esteban, Ponce de Leon Dario

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

Long-term real-world management of inflammatory rheumatic diseases remains unclear, especially with the advent of new treatment options. This study characterizes the number of advanced treatments used by patients with selected rheumatic diseases (rheumatoid arthritis [RA], psoriatic arthritis [PsA], ankylosing spondylitis, juvenile idiopathic arthritis) and provides a contemporary portrait of treatment patterns and therapeutic sequencing among patients with RA and PsA.

METHOD: Patients were selected from a large US claims database and classified into disease subsamples based on the latest rheumatic diagnosis recorded before/on the day of initiation of the first advanced treatment (index date). The total number of advanced treatments was assessed within the first 5 years following the index date. Treatment patterns and therapeutic sequencing were assessed over the first 2 years.

RESULTS

Approximately 20% of patients received ≥2 distinct advanced treatments during the first year following index date - the proportion increased to almost 50% among patients with 5 years of observation. Most patients (RA: 76.8%; PsA: 88.7%) initiated a tumor necrosis factor as the first advanced treatment. Over the first 2 years after the index date, 1/3 of RA and PsA patients switched to another advanced treatment. More than 50% initiated a second treatment with the same mechanism of action (MOA). A small proportion of patients received a biosimilar.

CONCLUSION

Despite advent of treatments with different MOA, cycling between treatments with the same MOA was common. Further studies with longer data follow-up would be needed to assess the impact of higher adoption of biosimilars on treatment patterns/sequencing.

Для цитирования: Gauthier Genevieve, Levin Rebecca, Vekeman Francis, Reyes Juan Manuel, Chiarello Esteban, Ponce de Leon Dario. Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis.. Current medical research and opinion. 2021. DOI: 10.1080/03007995.2021.1981278.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.